{"filings":[{"id":143715,"accession_number":"0001641172-25-022271","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["3.01","5.02","8.01"],"status":"ready","headline":"Ocean Biomedical faces Nasdaq delisting; CFO and director resign","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq Board declined to review Listing Council decision; final delisting action triggered under Rule 5830 and SEC Rule 12d2-2.","Director Michael Petersen resigned effective August 31, 2025; no disagreement cited.","CFO Jolie Kahn resigned effective August 5, 2025; no disagreement cited.","Company continues to work on previously announced power and cryptocurrency strategies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143714,"accession_number":"0001641172-25-020730","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Ocean Biomedical receives Nasdaq delisting affirmation; shares to be suspended","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Listing Council affirms Nasdaq's decision to delist Ocean Biomedical securities, effective April 24, 2025.","Company had appealed the Panel's April 22, 2025 delisting decision, but the appeal was denied.","Trading suspension to begin at opening of business on April 24, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143713,"accession_number":"0001641172-25-019924","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Ocean Biomedical's material licenses terminated by Elkurt due to uncured breach; old obligations remain","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elkurt, Inc. terminated all Ocean Biomedical licenses effective July 10, 2025, following an uncured material breach after 30-day cure period expired.","Termination notice states Ocean failed to cure breaches identified in Elkurt's June 9, 2025 notice.","All pre-termination obligations under the licenses, including unpaid amounts, remain continuing obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161936,"accession_number":"0001641172-25-015129","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Ocean Biomedical receives termination of key license agreements for alleged breaches totaling $612,581","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elkurt, Inc. terminated four Elias Agreements and one Kurtis lab license, plus a RIH license, effective June 9, 2025.","Alleged material breaches include unpaid obligations of $612,581.16 and failure to meet development milestones.","Ocean also failed to file an IND by June 30, 2024, for one milestone and faces three more IND deadlines by June 30, 2025.","Brown University has initiated termination of its licenses to Elkurt, which would further cut Ocean's access to the technology.","The notice states termination is immediate under Section 10.2.2.1 after failure to cure within 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161935,"accession_number":"0001641172-25-005788","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["3.01","5.02","8.01","9.01"],"status":"ready","headline":"Ocean Biomedical receives Nasdaq delisting notice, plans to appeal; expands into energy and crypto","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq determined OCEA common stock will be delisted and trading suspended effective April 24, 2025.","Company intends to appeal the delisting determination within 15 days but warns no guarantee of success.","Director Jake Kurtis resigned immediately on April 22, 2025 to pursue other interests.","Strategic expansion into power infrastructure and cryptocurrency treasury (Bitcoin and Solana) announced.","No specific financial commitments, project sizes, or capital sources disclosed for the new sectors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161934,"accession_number":"0001641172-25-002074","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Ocean Biomedical shareholders approve reverse split; CEO Michelle Berrey and multiple directors resign","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Michelle Berrey resigned; also resigned as director along with Jack Elias, Bill Owens, Suren Ajjarapu, Amy Griffith.","Stockholders approved reverse stock split in range of 1:2 to 1:250 (43.7M for, 15.8M against).","Elected directors: Chirinjeev Kathuria (28.5M for), Elizabeth Ng (30.3M), Jonathan Kurtis (30.6M), Michael Peterson (30.5M).","2025 Equity Compensation Plan approved (28.8M for, 4.1M against).","Non-binding say-on-pay frequency set to three years (27.2M for three years, 3.2M for two, 1.8M for one)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179997,"accession_number":"0001641172-25-000747","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Ocean Biomedical lowers note conversion price to $0.01 per share on $400K amount","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Conversion price on $400K promissory note reduced irrevocably from $1.50 to $0.01 per share.","Company may not redeem or prepay the $400K Reduced Conversion Amount.","Note originally issued on May 15, 2023 to an institutional investor.","Change triggers potential dilution by allowing conversion at near-zero price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179996,"accession_number":"0001493152-25-011046","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Ocean Biomedical receives Nasdaq delisting notice for low-priced stock rule; bid price <=$0.10 for 10 days","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Ocean Biomedical on March 14, 2025, that stock closed at $0.10 or less for 10 consecutive trading days.","This triggers the Low Priced Stocks Rule (Listing Rule 5810(c)(3)(A)(iii)), an additional basis for delisting.","Company already faced non-compliance with $1 minimum bid price (notified Dec 3, 2024); compliance period ends June 2, 2025.","Company must submit a letter to Nasdaq Hearings Panel by March 21, 2025, to address the new deficiency.","Panel will consider this matter in its decision on continued listing on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179995,"accession_number":"0001493152-25-009707","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Amy Griffith resigns from Ocean Biomedical board; company seeking replacements for multiple vacancies","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Amy Griffith resigned from the Board effective as of the Annual Meeting.","Company is actively seeking two independent directors to fill vacancies.","Previously announced that directors Ownes, Elias, Ajjarpu, and Berry will not stand for reelection."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179994,"accession_number":"0001493152-25-008395","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["3.02","5.03","9.01"],"status":"ready","headline":"Ocean Biomedical issues up to 45,000 Series A convertible preferred shares at $0.01 for reverse split vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["45,000 shares of Series A preferred issued at $0.01/share; convertible into common at $0.01/share after stockholder approval of reverse split.","Holders get 2,000 votes per share solely on the reverse stock split proposal; agree to vote in same proportion as common holders.","Redemption right arises after authorized share increase approval or 90 days from closing, until 120 days after closing.","Net proceeds used for general corporate purposes if shares not redeemed or converted; total potential raise is $450.","Issuance exempt from registration under Section 4(a)(2) and Regulation D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179993,"accession_number":"0001493152-25-007933","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["5.03"],"status":"ready","headline":"Ocean Biomedical amends bylaws to set quorum at 1/3 of outstanding shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment changes shareholder meeting quorum from previous level to 1/3 of shares outstanding as of record date.","Board of Directors approved the bylaw amendment on February 14, 2025.","Effective as of February 14, 2025; no other changes to bylaws disclosed.","Company remains an emerging growth company under SEC rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179992,"accession_number":"0001493152-25-006180","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["3.02","8.01"],"status":"ready","headline":"Ocean Biomedical discloses 132,163,312 shares outstanding as of Feb 11, 2025","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Issued and outstanding common stock as of February 11, 2025: 132,163,312 shares.","No press release or other exhibits accompanied the filing.","No context on capital structure changes or prior share count provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179991,"accession_number":"0001493152-25-002237","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Ocean Biomedical receives Nasdaq delisting notice for failure to hold annual meeting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Ocean Biomedical on Jan 7, 2025, that it failed to hold an annual meeting within 12 months of FY2023 end, violating Rule 5620(a).","This deficiency serves as an additional basis for delisting; the Nasdaq Hearings Panel will consider it in the ongoing listing review.","Company must submit views by Jan 14, 2025, and plans to hold annual meeting no later than March 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196788,"accession_number":"0001493152-24-050414","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"Ocean Biomedical appoints Berkowitz Pollack Brant as auditor for FY2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee approved engagement of Berkowitz Pollack Brant on Dec 17, 2024.","BPB will serve as independent registered public accounting firm for fiscal year ending Dec 31, 2024.","No prior consultation with BPB on accounting principles or audit disagreements during past two fiscal years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196787,"accession_number":"0001493152-24-049647","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Ocean Biomedical receives Nasdaq delisting notice for failing MVLS minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Ocean Biomedical on Dec 5, 2024 that its MVLS was below $35M for 30 consecutive business days.","Company has 180 calendar days to regain compliance by closing MVLS at $35M+ for 10 consecutive business days.","Failure to cure within the compliance period may result in delisting of common stock and warrants from Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196786,"accession_number":"0001493152-24-049281","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Ocean Biomedical fails Nasdaq minimum bid price rule; given 180 days to comply","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Ocean Biomedical of non-compliance with minimum $1 bid price rule on Dec 3, 2024.","Closing bid price below $1 for 30 consecutive business days ended Dec 2, 2024.","Company has 180 days, until June 2, 2025, to regain compliance.","To regain compliance, bid price must close at $1 for 10 consecutive business days.","If not compliant by June 2, 2025, may be eligible for extra time or face delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196785,"accession_number":"0001493152-24-049099","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2024-12-06T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Ocean Biomedical dismisses Deloitte & Touche as independent auditor effective Dec. 2, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed Deloitte & Touche LLP as independent registered public accounting firm effective December 2, 2024.","No disagreements with Deloitte on accounting principles, financial statement disclosure, or audit scope during fiscal 2022–2023 or interim period through Dec. 2, 2024.","Deloitte's prior reports contained a going concern explanatory paragraph citing working capital deficiency and anticipated losses.","Board approved the change by written consent on December 2, 2024.","Company requested Deloitte to furnish a letter to the SEC agreeing with the statements; letter attached as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196784,"accession_number":"0001493152-24-047421","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Ocean Biomedical faces Nasdaq delisting over late Q3 2024 10-Q; hearing Dec 16","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Nov 18, 2024 for failure to file Form 10-Q for period ended Sep 30, 2024.","This is an additional basis for delisting; prior delinquencies include 2023 10-K and Q1/Q2 2024 10-Qs.","Nasdaq Hearings Panel will consider the matter at hearing scheduled for December 16, 2024.","Company intends to file delinquent reports as soon as practicable; no immediate effect on trading."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196783,"accession_number":"0001493152-24-042911","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CEO Elizabeth Ng takes sabbatical; Director M. Michelle Berrey appointed Interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Elizabeth Ng notified Board on Oct 23, 2024 of sabbatical for personal reasons.","Director M. Michelle Berrey appointed Interim CEO, effective immediately.","Compensation arrangements for Interim CEO not yet determined; will be disclosed later."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196782,"accession_number":"0001493152-24-042071","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2024-10-22T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Ocean Biomedical receives Nasdaq delisting determination for missing filing deadlines","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified company on Oct 16, 2024 that it failed to file Form 10-K for 2023 and Forms 10-Q for Q1 and Q2 2024.","Exception granted until Oct 14, 2024 was not met; company has not filed the required reports.","Company will appeal the Staff determination to a Nasdaq Hearings Panel under Rule 5800 Series.","Ticker OCEA and OCEAW remain listed pending appeal; outcome uncertain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196781,"accession_number":"0001493152-24-041436","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2024-10-17T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ocean Biomedical ratifies revised Virion agreement to acquire up to 22% stake for $9M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Board ratified revised agreement dated Nov 2023, received Sep 26, 2024; Ocean to own 22% of Virion fully diluted.","$9M aggregate capital contribution paid via cash and/or equity; $960k already credited.","Virion will sell 500,000 OCEA shares held; proceeds count toward $9M.","If proceeds below $9M by Apr 1, 2025, Ocean may pay difference in cash or stock.","Max common interests: 10,933,155; initial 1,166,203 already issued (2.34% as of Aug 21, 2024)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213091,"accession_number":"0001493152-24-033729","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2024-08-23T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Ocean Biomedical receives Nasdaq notice for late 10-Q filing; must file delinquent reports by Oct 14","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Aug 19, 2024 for failure to file Q2 2024 Form 10-Q on time.","Must submit compliance plan by Sept 3, 2024; all delinquent reports due by Oct 14, 2024.","Delinquent reports include Q1 2024 10-Q, Q2 2024 10-Q, and 2023 10-K.","No immediate effect on listing, but further delays risk delisting.","Company states it intends to file as soon as practicable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213090,"accession_number":"0001493152-24-028844","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Ocean Biomedical secures up to $7.675M financing, issues 3.8M shares to settle defaults","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Up to $7.675M additional secured notes; first $1.1M tranche used for 2023 audit and quarterly reporting costs.","Existing defaults cured; maturity extended to Dec 15, 2024; installment payments waived until Sept 1 or 10-K filing.","Issued 3,844,466 restricted shares and 1,332,806 warrants to institutional investor for past defaults and penalty shares.","Amended earnout shares: 18M shares to be issued in three tranches of 6M each now and on anniversaries.","Settled $2.7M promissory notes with two institutional investors via shares and cash or deferred shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232201,"accession_number":"0001493152-24-021880","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Ocean Biomedical receives Nasdaq non-compliance notice for late Q1 2024 10-Q filing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice received May 22, 2024 due to failure to file Form 10-Q for period ended March 31, 2024.","Company must submit a plan to regain compliance by June 14, 2024, and file delinquent 10-Q by October 14, 2024.","No immediate effect on listing or trading of OCEA common stock or OCEAW warrants, but further delays could impact.","Ocean Biomedical cites previously disclosed delays from its 2023 10-K as the cause.","Company intends to file the delinquent Form 10-Q as soon as practicable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232200,"accession_number":"0001493152-24-015820","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2024-04-24T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Ocean Biomedical receives Nasdaq deficiency notice for late 10-K filing; must file by Oct 14, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on April 18, 2024 for non-compliance with Listing Rule 5250(c)(1) due to late filing of Form 10-K for FY2023.","Must submit a compliance plan by June 14, 2024 and file delinquent Form 10-K by October 14, 2024 to regain listing compliance.","No immediate effect on stock trading, but further delays could impact listing; company intends to file as soon as practicable.","Delay stems from previously disclosed issues with amended 10-Qs for first two quarters and 10-Q for third quarter of 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250474,"accession_number":"0001493152-24-009436","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Ocean Biomedical appoints Amy Griffith to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Amy Griffith appointed director effective March 4, 2024; brings government relations expertise.","Currently Head, Government Relations & External Affairs for McCain Foods - North America.","Prior roles include Coca-Cola Group Director NA, Wells Fargo SVP Government Relations, TIAA.","Also serves as independent director at AgriFORCE Growing Systems, chairs governance committee.","Appointment expands board with regulatory and public policy experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250473,"accession_number":"0001493152-24-008720","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Ocean Biomedical appoints Jolie Kahn as CFO effective March 1; predecessor Kalra resigned Jan 30","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gurinder Kalra resigned as CFO effective January 30, 2024 to pursue other interests.","Jolie Kahn was confirmed as CFO on March 1, 2024; she also serves as legal counsel to the company.","Kahn has corporate finance and securities law background; prior CFO roles at GlucoTrack (2019-2023) and interim CFO at ToughBuilt.","Compensation: $22,500 per month for CFO and counsel services."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250472,"accession_number":"0001493152-24-003091","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2024-01-19T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Ocean Biomedical notified by Nasdaq of MVLS below $35M minimum; 180 days to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Ocean Biomedical on Jan 17, 2024 that its MVLS was below $35M minimum for 30 consecutive business days.","Company has until July 15, 2024 to regain compliance; MVLS must close at $35M+ for 10 consecutive business days.","If not compliant by July 15, Nasdaq may delist; company can appeal to a Hearings Panel.","No immediate effect on trading; stock continues trading under symbol OCEA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250471,"accession_number":"0001493152-24-002701","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2024-01-17T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Ocean Biomedical receives Nasdaq bid price deficiency notice; must regain compliance by July 9, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Closing bid price of common stock (OCEA) below $1.00 for 30 consecutive business days through Jan 10, 2024.","180-day cure period ends July 9, 2024; compliance requires $1.00 closing bid for 10 consecutive business days.","Company may seek 180-day extension if it meets other listing standards and notifies Nasdaq of intent to cure via reverse stock split.","If not cured, Nasdaq will delist common stock; company can appeal to a Hearings Panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":268025,"accession_number":"0001493152-23-043107","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2023-11-30T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Ocean Biomedical receives Nasdaq delinquency notice for late 10-Q; will restate Q1/Q2 2023 results","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Ocean Biomedical on Nov 22, 2023 for non-compliance with Listing Rule 5250(c)(1) due to late Form 10-Q.","Company must submit compliance plan by Jan 22, 2024 and file delinquent Form 10-Q by May 20, 2024.","Will restate Q1 and Q2 2023 financials based on new SEC interpretation on accounting for backstop agreements.","Backstop agreements with Vellar Opportunity Fund SPV LLC-Series 3, Meteora entities, and Polar Multi-Strategy Master Fund.","No immediate effect on listing/trading; further delays could impact compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":268024,"accession_number":"0001493152-23-041387","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2023-11-15T23:59:59+00:00","items":["4.02","9.01"],"status":"ready","headline":"Ocean Biomedical restates Q1/Q2 2023 financials over Backstop Agreement classification error","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee on Nov 10 concluded prior Q1 and Q2 2023 financials should no longer be relied upon.","Issue follows SEC Staff interpretation on Forward Purchase Agreements; prepayment recorded as asset instead of equity.","Prepaid forward transaction and minimum maturity consideration should be classified as liabilities.","Prior earnings releases, guidance, and investor communications referencing those statements also unreliable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":268023,"accession_number":"0001493152-23-037068","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2023-10-12T23:59:59+00:00","items":["1.01","2.01","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Ocean Biomedical acquires 50% of Virion Therapeutics for $4.1M cash or 750k shares","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired 50% ownership in Virion, a clinical-stage T cell immunotherapy company, for $4.1M cash or 750k shares of common stock.","Virion is enrolling first-in-human Phase 1b study VRON-0200 for chronic HBV; expects first data in next few months.","Ocean may contribute additional cash/shares to support Virion's clinical trial and R&D, including oncology IND submission within 9 months.","Director Jerome Ringo resigned on Oct 6, 2023, with no dispute with the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":268022,"accession_number":"0001493152-23-036565","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2023-10-06T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Ocean Biomedical announces $10M convertible debt term sheet from largest stockholder; amends equity facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-binding term sheet for up to $10M convertible notes from largest stockholder Poseidon Bio at $10.34 conversion, $11.50 warrants, 1-year maturity.","Amendment to White Lion equity line allows fixed purchases at $7.00/share when stock price >=$9.00, up to 50,000 shares per notice.","No shares have been issued under the original $75M common stock purchase agreement with White Lion.","Proposed debt facility is unsecured, junior to senior lender, and requires senior lender consent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":268021,"accession_number":"0001493152-23-035098","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2023-10-03T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Ocean Biomedical amends VWAP trigger and reset price in side letter with Polar","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Side letter dated October 2, 2023 amends definitions for Polar under Feb 2023 Novation Agreement.","Seller VWAP Trigger Event occurs if VWAP below $2.50 for 20 of 30 consecutive trading days.","Reset Price set at $8.00, subject to reduction via Dilutive Offering Reset.","Amendment applies only to Polar's 2,666,667 shares under the Forward Purchase Agreement.","All other terms of Novation and Forward Purchase Agreements remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285263,"accession_number":"0001493152-23-031878","cik":1869974,"company_name":"Ocean Biomedical, Inc.","ticker":"OCEA","form_type":"8-K","filed_at":"2023-09-06T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Stockholders approve Nasdaq Proposal for share issuance from convertible notes and warrant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting held Aug 30, 2023; 25,756,950 shares present (~75.6% of 34,062,724 outstanding).","Vote: 25,268,869 for, 472,508 against, 15,573 abstain on the Nasdaq Proposal.","Proposal allows potential conversion of up to three Senior Secured Convertible Notes and warrant under May 15 SPA.","Only one $7.56M note issued to date; ~24,400 shares issued for accrued interest; no warrant exercised.","Full conversion of current note would equal ~2% of outstanding common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":69710.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}